Emergent BioSolutions | EBS - Net Income


Emergent BioSolutions reported $-261.3M in Net Income for its fiscal quarter ending in June of 2023.





Net Income Change Date
Acadia Pharmaceuticals USD 273.57M 201.79M Dec/2025
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
ALKERMES USD 49.34M 33.42M Dec/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Amarin USD -1.22M 6.51M Dec/2025
ANI Pharmaceuticals USD 32.35M 6.08M Dec/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Coherus Biosciences USD -37.64M 2.11M Dec/2025
Emergent BioSolutions USD -261.3M 78.3M Jun/2023
Exelixis USD 193.58M 8.73M Sep/2025
Glaxosmithkline GBP 846.06M 1.87B Dec/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
Ironwood Pharmaceuticals USD 3.19M 457K Dec/2024
Lexicon Pharmaceuticals USD -15.53M 2.76M Dec/2025
Lonza CHF 426M 119M Jun/2025
Merck USD 2.96B 2.82B Dec/2025
Moderna USD -200M 625M Sep/2025
Myriad Genetics USD -7.9M 19.5M Dec/2025
Nektar Therapeutics USD -36.08M 978K Dec/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
Pacira USD 1.64M 3.8M Dec/2025
Pfizer USD -1.65B 5.19B Dec/2025
PTC Therapeutics USD -134.96M 150.86M Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
Sarepta Therapeutics USD -412.23M 232.28M Dec/2025
United Therapeutics USD 364.3M 25.6M Dec/2025
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024
Xoma USD -17.24M 33.23M Sep/2024